Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice

Arthritis and Rheumatism

Volumn 62, Issue 5, 2010, Pages 1457-1468

  Ramanujam, Meera ^a,b   Bethunaickan, Ramalingam ^b   Huang, Weiqing ^b   Tao, Haiou ^b   Madaio, Michael P ^c   Davidson, Anne ^b  

^a CENTOCOR INC   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GLOMERULOSCLEROSIS; HEMATOPOIETIC STEM CELL; IMMUNE COMPLEX DEPOSITION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SEROLOGY; SPLEEN;

ANIMALS; ANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA; FLOW CYTOMETRY; IMMUNOGLOBULIN M; IMMUNOTHERAPY; LUPUS NEPHRITIS; MICE; MICE, INBRED NZB; MICE, MUTANT STRAINS; PHENOTYPE; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; SPLEEN;

EID: 77951739752     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27368     Document Type: Article

References (43)

1. Dooley MA. Clinical and laboratory features of SLE nephritis. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1112-1130
2. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-766
3. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006;65 Suppl III:iii34-6.
4. Thien M, Phan TG, Gardam S, AmesburyM, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798 (Pubitemid 38757447)
5. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-453 (Pubitemid 38482122)
6. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-551 (Pubitemid 46828489)
7. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-39 (Pubitemid 41129420)
8. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115:3083-3092
9. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008;180:1938-1947
10. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-275 (Pubitemid 44287558)
11. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-1178
12. Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003;170:4818-4825 (Pubitemid 36519992)
13. Erickson LD, Lin LL, Duan B, Morel L, Noelle RJ. A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci U S A 2003;100:12905-12910 (Pubitemid 37339998)
14. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724-734 (Pubitemid 43326881)
15. Mihara M, Tan I, Chuzhin Y, Reddy B, Budhai L, Holzer A, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101. (Pubitemid 30437244)
16. Shi X, Xie C, Kreska D, Richardson JA, Mohan C. Genetic dissection of SLE: SLE1 and FAS impact alternate pathways leading to lymphoproliferative autoimmunity. J Exp Med 2002;196:281-292 (Pubitemid 34875658)
17. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004;173:3524-3534 (Pubitemid 39142063)
18. Chan O, Madaio MP, Shlomchik MJ. The roles of B cells in MRL/lpr murine lupus. Ann N Y Acad Sci 1997;815:75-87. (Pubitemid 27309490)
19. Mohan C, Morel L, Yang P, Wakeland EK. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum 1998;41:1652-1662 (Pubitemid 28459925)
20. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302. (Pubitemid 32816877)
21. Li L, Huang L, Sung SS, Vergis AL, Rosin DL, Rose CE Jr, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008;74:1526-1537
22. + interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 2006;70:591-596
23. Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus - will the promise be fulfilled? Immunol Rev 2008;223:156-174
24. Kahn P, Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008;58:2824-2834
25. Cancro MP. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004;202:237-249
26. Rahman ZS, Rao SP, Kalled SL, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003;198:1157-1169 (Pubitemid 37323381)
27. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-98
28. Liu W, Szalai A, Zhao L, Liu D, Martin F, Kimberly RP, et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 2004;50:1884-1896 (Pubitemid 38725101)
29. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000;18:739-766 (Pubitemid 30365396)
30. Blenman KR, Duan B, Xu Z, Wan S, Atkinson MA, Flotte TR, et al. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest 2006;86:1136-1148 (Pubitemid 44624150)
31. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201-214
32. + phenotype controls T cell-dependent inflammatory responses. Immunity 2008;28:639-650
33. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, et al. In vivo analysis of dendritic cell development and homeostasis. Science 2009;324:392-397
34. Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci U S A 2008;105:14993-14998
35. Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol 2008;180:7394-7403
36. Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 2006;177:7287-7295 (Pubitemid 44715098)
37. Seery JP, Cattell V, Watt FM. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(β-o-methyl)- fluoromethylketone. J Immunol 2001;167:2452-2455 (Pubitemid 32768869)
38. 1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003;171:489-497
39. Salmon AH, Neal CR, Harper SJ. New aspects of glomerular filtration barrier structure and function: five layers (at least) not three. Curr Opin Nephrol Hypertens 2009;18:197-205.
40. Shankland SJ. The podocyte's response to injury: role in protein-uria and glomerulosclerosis. Kidney Int 2006;69:2131-2147 (Pubitemid 43882099)
41. Herlands RA, William J, Hershberg U, Shlomchik MJ. Antichromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur J Immunol 2007;37:3339-3351
42. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010;62:201-210
43. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098-3107